Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- I Get Marriage Proposals Every Day
- Media Experts Seek Stronger African Action Against South Africa’s Xenophobic Violence – THISDAYLIVE
- ‘We are focusing on the boy-child with skill sets, exposures that change negative perceptions’
- Trump orders new 15% tariff on key material for solar panels and microchips | Trump administration
- US strikes $1.2bn deal to pay German firm to halt offshore wind projects
- Van Barneveld fined and suspended over inappropriate behaviour and offensive language in latest Darts Regulation Authority case list | Darts News
- Brandon Flowers Looks Back at the Past on Single ‘Tiger’s Blood’
- Aina Bridges Music, Theatre, Healthcare in a Growing Creative Career – THISDAYLIVE
